Androgen insensitivity syndrome overview: Difference between revisions
| (35 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Androgen insensitivity syndrome}} | {{Androgen insensitivity syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{ARK}} | ||
==Overview== | ==Overview== | ||
Androgen insensitivity syndrome (AIS | Androgen insensitivity syndrome is due to hormone resistance which may be due to defective [[androgen receptor]] ([[Androgen receptor|AR]]) function by either abnormal [[androgen receptor]] ([[Androgen receptor|AR]]) binding, decreased receptor binding, or impaired [[androgen receptor]] ([[Androgen receptor|AR]]) binding. AIS is an [[X linked]] disorder. The development of Androgen insensitivity syndrome is a result of [[genetic mutations]] of the [[androgen receptor]] ([[Androgen receptor|AR]]) gene located on the chromosome Xq11-12. Associated conditions include [[primary amenorrhea]], [[infertility]] and [[dyspareunia]]. [[Androgen receptor]] ([[Androgen receptor|AR]]) gene defects inhibit the normal development of both internal and external genital structures in 46XY individuals, causing a variety of [[phenotypes]] ranging from [[male infertility]] to completely normal female [[external genitalia]]. Androgen insensitivity syndrome (AIS) represents a spectrum of defects in androgen action and can be subdivided into three broad phenotypes such as complete, partial and mild AIS. A multidisciplinary approach is recommended for clinical management from infancy through to adulthood. Hormone replacement therapy is needed following gonadectomy. Patients who have decided to retain their gonads are considered to be at risk for developing germ cell tumors and for these the sensitive circulating tumor markers may become available soon. Surgical approach to the Androgen insensitivity syndrome involves vaginal [[dilation]] or gonadectomy or determination of sex which depend on various factors such as the type of AIS, age, sex and preventive measures to be taken in adolescence and adulthood. | ||
==Historical Perspective== | ==Historical Perspective== | ||
In 1953, the first medical report on AIS was published by J. M. Morris, an american gynecologist. In 1989, the exact location of the human Androgen receptor (AR) gene on Xq11-12 locus was determined and the proof that it is caused by mutations in this gene. | |||
==Classification== | ==Classification== | ||
Androgen insensitivity syndrome (AIS) represents a spectrum of defects in androgen action and can be subdivided into three broad phenotypes such as | Androgen insensitivity syndrome (AIS) represents a spectrum of defects in androgen action and can be subdivided into three broad phenotypes such as complete, partial and mild AIS. | ||
==Pathophysiology== | ==Pathophysiology== | ||
Androgen insensitivity syndrome | It is thought that Androgen insensitivity syndrome is caused due to hormone resistance which may be due to defective [[androgen receptor]] ([[Androgen receptor|AR]]) function by either abnormal [[androgen receptor]] ([[Androgen receptor|AR]]) binding, decreased receptor binding, or impaired [[androgen receptor]] ([[Androgen receptor|AR]]) binding. AIS is an [[X linked]] disorder. The development of Androgen insensitivity syndrome is a result of [[genetic mutations]] of the [[androgen receptor]] ([[Androgen receptor|AR]]) gene located on the chromosome Xq11-12. Associated conditions include [[primary amenorrhea]], [[infertility]] and [[dyspareunia]]. | ||
==Causes== | ==Causes== | ||
Androgen insensitivity syndrome is caused due to mutations in the X-linked androgen receptor gene. AR gene defects inhibit the normal development of both internal and external genital structures in | Androgen insensitivity syndrome is caused due to [[mutations]] in the [[X-linked]] [[androgen receptor]] gene. [[Androgen receptor]] ([[Androgen receptor|AR]]) gene defects inhibit the normal development of both internal and external genital structures in 46XY individuals, causing a variety of [[phenotypes]] ranging from [[male infertility]] to completely normal female [[external genitalia]]. | ||
==Differentiating Androgen insensitivity syndrome from Other Diseases== | ==Differentiating Androgen insensitivity syndrome from Other Diseases== | ||
Androgen insensitivity syndrome | Androgen insensitivity syndrome must be differentiated from other conditions based on the genotype, phenotype and developmental characteristics. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
CAIS has a prevalence of 2 per 100,000 to 5 per 100,000. The incidence of complete AIS is about in 5 in 100,000 | CAIS has a [[prevalence]] of 2 per 100,000 to 5 per 100,000. The [[incidence]] of complete AIS is about in 5 in 100,000. There is no racial predilection for androgen insensitivity syndrome. | ||
==Risk Factors== | ==Risk Factors== | ||
The risk of gonadal germ cell tumor is low during childhood and adolescence but increases in later adulthood. Benign | The risk of gonadal [[germ cell tumor]] is low during childhood and [[adolescence]] but increases in later adulthood. [[Benign tumors]] of [[nongerminomatous germ cell tumor]] include [[Sertoli cell]] adenoma and [[hamartomas]]. | ||
==Screening== | ==Screening== | ||
The diagnosis of AIS is mostly made post-natally. Studies have shown that the AIS may be identified prenatally by imaging techniques and comparative study such as [[Preimplantation genetic diagnosis|preimplantation genetic screening]], noninvasive [[prenatal screening]] and [[ultrasonography]]. | |||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
If left untreated, androgen insensitivity syndrome may lead to cancers of the [[male breast]], [[larynx]], [[liver]], [[testes]] and [[bladder]]. Common complications of androgen insensitivity syndrome include [[Infertility]], [[psychological]] and social issues, [[osteoporosis]], and [[cancers]]. Prognosis is good after [[orchidectomy]] at the proper time. For incomplete AIS patients, it depends on the presence and severity of [[ambiguous genitalia]]. | |||
==Diagnosis== | ==Diagnosis== | ||
===History and Symptoms=== | ===History and Symptoms=== | ||
The diagnosis of AIS is determined in a 46,XY individual by the undermasculinization of the external genitalia, impaired spermatogenesis and absent or rudimentary müllerian structures. Cases of CAIS are diagnosed during abdominal surgery, delayed menarche and infertility. | The diagnosis of AIS is determined in a 46,XY individual by the undermasculinization of the external genitalia, impaired [[spermatogenesis]] and absent or rudimentary [[Müllerian duct|müllerian]] structures. Cases of CAIS are diagnosed during abdominal surgery, delayed [[menarche]] and [[infertility]]. | ||
===Physical Examination=== | ===Physical Examination=== | ||
Androgen insensitivity syndrome (AIS) is typically characterized by evidence of feminization (i.e., undermasculinization) of the external genitalia at birth, abnormal secondary sexual development in puberty, and infertility in individuals with a 46,XY karyotype. | Androgen insensitivity syndrome (AIS) is typically characterized by evidence of feminization (i.e., undermasculinization) of the external genitalia at birth, abnormal secondary sexual development in [[puberty]], and [[infertility]] in individuals with a 46,XY karyotype. | ||
===Laboratory Findings=== | ===Laboratory Findings=== | ||
Laboratory findings which suggest the presence of normal or increased synthesis of testosterone and its normal conversion to [[dihydrotestosterone]], and normal or increased [[luteinizing hormone]] (LH) production by the [[pituitary gland]] AND/OR by the identification of a [[hemizygous]] pathogenic variant. | |||
=== | ===Electrocardiogram=== | ||
There are no | There are no ECG findings observed in androgen insensitivity syndrome. | ||
===X-ray=== | |||
There are no X-ray findings associated with androgen insensitivity syndrome. | |||
===Ultrasound=== | |||
Pelvic ultrasound helps in determining the presence or absence of uterus and gonads. | |||
===CT scan=== | |||
Findings of seminoma are observed by FDG PET/CT in androgen insensitivity syndrome. Incidental detection of sertoli-Leydig cell tumor by FDG PET/CT imaging. | |||
===MRI=== | |||
MRI may be helpful in the diagnosis of Androgen insensitivity syndrome. MRI may be helpful in localizing the testes, diagnosing malignancy in cryptorchid testes and describing mullerian duct anomalies. | |||
===Other Imaging Findings=== | |||
There are no other imaging findings associated with androgen insensitivity syndrome. | |||
===Other Diagnostic Studies=== | ===Other Diagnostic Studies=== | ||
There are other diagnostic studies associated with androgen insensitivity syndrome. | There are no other diagnostic studies associated with androgen insensitivity syndrome. | ||
==Treatment== | ==Treatment== | ||
===Medical Therapy=== | ===Medical Therapy=== | ||
A multidisciplinary approach is recommended for clinical management from infancy through to adulthood. Hormone replacement therapy is needed following gonadectomy. Patients who choose to retain the gonads are at risk of developing germ cell tumors for which sensitive circulating tumor markers may soon become available. | A multidisciplinary approach is recommended for clinical management from infancy through to adulthood. [[Hormone replacement therapy]] is needed following gonadectomy. Patients who choose to retain the [[gonads]] are at risk of developing [[germ cell tumors]] for which sensitive circulating [[tumor markers]] may soon become available. | ||
===Surgery=== | ===Surgery=== | ||
Surgical approach to the Androgen insensitivity syndrome involves vaginal dilation or gonadectomy or determination of sex which depend on various factors such as the type of AIS, age, sex and preventive measures to be taken in adolescence and adulthood. | Surgical approach to the Androgen insensitivity syndrome involves vaginal [[dilation]] or gonadectomy or determination of sex which depend on various factors such as the type of AIS, age, sex and preventive measures to be taken in adolescence and adulthood. | ||
===Prevention=== | ===Prevention=== | ||
Currently there are no established methods to prevent androgen insensitivity syndrome (AIS). However, various treatment options may help manage the symptoms of AIS. Genetic counseling is advisable for parents as well as the affected individuals. The use of preimplantation genetic screening, noninvasive prenatal screening and ultrasonography and laparoscopic surgery may help identify, prevent or rectify accordingly. Women with CAIS have decreased bone mineral density, regardless of timing of gonadectomy. | Currently there are no established methods to prevent androgen insensitivity syndrome (AIS). However, various treatment options may help manage the symptoms of AIS. Genetic counseling is advisable for parents as well as the affected individuals. The use of preimplantation genetic screening, noninvasive [[prenatal screening]] and [[ultrasonography]] and [[laparoscopic surgery]] may help identify, prevent or rectify accordingly. Women with CAIS have decreased bone mineral density, regardless of timing of gonadectomy. | ||
==References== | ==References== | ||
Latest revision as of 13:59, 19 October 2017
|
Androgen insensitivity syndrome Microchapters |
|
Differentiating Androgen insensitivity syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Androgen insensitivity syndrome overview On the Web |
|
American Roentgen Ray Society Images of Androgen insensitivity syndrome overview |
|
Directions to Hospitals Treating Androgen insensitivity syndrome |
|
Risk calculators and risk factors for Androgen insensitivity syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]
Overview
Androgen insensitivity syndrome is due to hormone resistance which may be due to defective androgen receptor (AR) function by either abnormal androgen receptor (AR) binding, decreased receptor binding, or impaired androgen receptor (AR) binding. AIS is an X linked disorder. The development of Androgen insensitivity syndrome is a result of genetic mutations of the androgen receptor (AR) gene located on the chromosome Xq11-12. Associated conditions include primary amenorrhea, infertility and dyspareunia. Androgen receptor (AR) gene defects inhibit the normal development of both internal and external genital structures in 46XY individuals, causing a variety of phenotypes ranging from male infertility to completely normal female external genitalia. Androgen insensitivity syndrome (AIS) represents a spectrum of defects in androgen action and can be subdivided into three broad phenotypes such as complete, partial and mild AIS. A multidisciplinary approach is recommended for clinical management from infancy through to adulthood. Hormone replacement therapy is needed following gonadectomy. Patients who have decided to retain their gonads are considered to be at risk for developing germ cell tumors and for these the sensitive circulating tumor markers may become available soon. Surgical approach to the Androgen insensitivity syndrome involves vaginal dilation or gonadectomy or determination of sex which depend on various factors such as the type of AIS, age, sex and preventive measures to be taken in adolescence and adulthood.
Historical Perspective
In 1953, the first medical report on AIS was published by J. M. Morris, an american gynecologist. In 1989, the exact location of the human Androgen receptor (AR) gene on Xq11-12 locus was determined and the proof that it is caused by mutations in this gene.
Classification
Androgen insensitivity syndrome (AIS) represents a spectrum of defects in androgen action and can be subdivided into three broad phenotypes such as complete, partial and mild AIS.
Pathophysiology
It is thought that Androgen insensitivity syndrome is caused due to hormone resistance which may be due to defective androgen receptor (AR) function by either abnormal androgen receptor (AR) binding, decreased receptor binding, or impaired androgen receptor (AR) binding. AIS is an X linked disorder. The development of Androgen insensitivity syndrome is a result of genetic mutations of the androgen receptor (AR) gene located on the chromosome Xq11-12. Associated conditions include primary amenorrhea, infertility and dyspareunia.
Causes
Androgen insensitivity syndrome is caused due to mutations in the X-linked androgen receptor gene. Androgen receptor (AR) gene defects inhibit the normal development of both internal and external genital structures in 46XY individuals, causing a variety of phenotypes ranging from male infertility to completely normal female external genitalia.
Differentiating Androgen insensitivity syndrome from Other Diseases
Androgen insensitivity syndrome must be differentiated from other conditions based on the genotype, phenotype and developmental characteristics.
Epidemiology and Demographics
CAIS has a prevalence of 2 per 100,000 to 5 per 100,000. The incidence of complete AIS is about in 5 in 100,000. There is no racial predilection for androgen insensitivity syndrome.
Risk Factors
The risk of gonadal germ cell tumor is low during childhood and adolescence but increases in later adulthood. Benign tumors of nongerminomatous germ cell tumor include Sertoli cell adenoma and hamartomas.
Screening
The diagnosis of AIS is mostly made post-natally. Studies have shown that the AIS may be identified prenatally by imaging techniques and comparative study such as preimplantation genetic screening, noninvasive prenatal screening and ultrasonography.
Natural History, Complications, and Prognosis
If left untreated, androgen insensitivity syndrome may lead to cancers of the male breast, larynx, liver, testes and bladder. Common complications of androgen insensitivity syndrome include Infertility, psychological and social issues, osteoporosis, and cancers. Prognosis is good after orchidectomy at the proper time. For incomplete AIS patients, it depends on the presence and severity of ambiguous genitalia.
Diagnosis
History and Symptoms
The diagnosis of AIS is determined in a 46,XY individual by the undermasculinization of the external genitalia, impaired spermatogenesis and absent or rudimentary müllerian structures. Cases of CAIS are diagnosed during abdominal surgery, delayed menarche and infertility.
Physical Examination
Androgen insensitivity syndrome (AIS) is typically characterized by evidence of feminization (i.e., undermasculinization) of the external genitalia at birth, abnormal secondary sexual development in puberty, and infertility in individuals with a 46,XY karyotype.
Laboratory Findings
Laboratory findings which suggest the presence of normal or increased synthesis of testosterone and its normal conversion to dihydrotestosterone, and normal or increased luteinizing hormone (LH) production by the pituitary gland AND/OR by the identification of a hemizygous pathogenic variant.
Electrocardiogram
There are no ECG findings observed in androgen insensitivity syndrome.
X-ray
There are no X-ray findings associated with androgen insensitivity syndrome.
Ultrasound
Pelvic ultrasound helps in determining the presence or absence of uterus and gonads.
CT scan
Findings of seminoma are observed by FDG PET/CT in androgen insensitivity syndrome. Incidental detection of sertoli-Leydig cell tumor by FDG PET/CT imaging.
MRI
MRI may be helpful in the diagnosis of Androgen insensitivity syndrome. MRI may be helpful in localizing the testes, diagnosing malignancy in cryptorchid testes and describing mullerian duct anomalies.
Other Imaging Findings
There are no other imaging findings associated with androgen insensitivity syndrome.
Other Diagnostic Studies
There are no other diagnostic studies associated with androgen insensitivity syndrome.
Treatment
Medical Therapy
A multidisciplinary approach is recommended for clinical management from infancy through to adulthood. Hormone replacement therapy is needed following gonadectomy. Patients who choose to retain the gonads are at risk of developing germ cell tumors for which sensitive circulating tumor markers may soon become available.
Surgery
Surgical approach to the Androgen insensitivity syndrome involves vaginal dilation or gonadectomy or determination of sex which depend on various factors such as the type of AIS, age, sex and preventive measures to be taken in adolescence and adulthood.
Prevention
Currently there are no established methods to prevent androgen insensitivity syndrome (AIS). However, various treatment options may help manage the symptoms of AIS. Genetic counseling is advisable for parents as well as the affected individuals. The use of preimplantation genetic screening, noninvasive prenatal screening and ultrasonography and laparoscopic surgery may help identify, prevent or rectify accordingly. Women with CAIS have decreased bone mineral density, regardless of timing of gonadectomy.